Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients (IMAGE)

Dana-Farber Cancer Institute

Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients

Caption

The study, highlighting a potential breakthrough in personalized cancer treatment, was led by clinical investigators at Dana-Farber Cancer Institute and Brigham and Women’s Hospital and published in the Journal of Clinical Oncology.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

Courtesy Dana-Farber Cancer Institute

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.